Rethinking attitudes towards success and failure

 The Tyranny of Merit. What's Become of the Common Good?

The economist's view (4)

 21st Century Economics_ Economic Ideas You Should Read and Remember

The peril of media capture

 Media Capture. HOW MONEY, DIGITAL PLATFORMS, AND GOVERNMENTS CONTROL THE NEWS

Platforms, a business model (5)

 The Platform Delusion. WHO WINS AND WHO LOSES IN THE AGE OF TECH TITANS

Behavioral Insights (2)

 Behavioral Insights

Key message,

Over the past ten years, there has been increasing interest in the idea of behavioral insights. However, at some point, this interest may start to end and attention may go elsewhere. Other ideas may come along, with their own compelling claims. People may stop deciding to “bring in” behavioral experts, as Rory was for autonomous vehicles. If this is true, then the immediate priority should be to integrate behavioral insights into the standard way that policy is made or organizations are run. That would mean that the practices are resilient to people no longer asking for “behavioral” solutions.

In fact, you could argue that this is the ultimate goal of the behavioral insights approach. The idea of a “behavioral” solution or approach should become meaningless, since the principles will have become absorbed into standard ways of working. Since, as we said in chapter 1, most policies or services concern behavior, then this is just about improving the way that central function is performed—it is not some kind of optional extra. Rather than talking about “behavioral public policy,” we would just refer to public policy (or corporate strategy) done better. In a sense, stopping talking about behavioral insights may actually be a sign that its true promise has been fulfilled. Until then, there is more to do.

The idea of a “behavioral” solution or approach should become meaningless, since the principles will have become absorbed into standard ways of working.

Risk-sharing agreements for drugs (3)

 Characterization of the Pharmaceutical Risk‑Sharing Arrangement Process in Catalonia

Table 1

Uncertainty type, scope, and considered variables for drug assessment

Uncertainty type	Uncertainty scope	Considered variables
Clinical	Efficacy, effectiveness, and safety	Time frame
		Clinical trial phase
		Patient characteristics
		Primary endpoint
		Surrogate endpoints
		Active comparator
		Sensitivity analysis
		Statistical analysis
		Patient subgroup analyses
		Time frames for treatment follow-up
Financial	BI and CE	Indication extension and concretion
		Treatment regimen
		Potentially replaceable treatments
		Net financial impact of treatment inclusion/replacement
		Potential use extensions
		Other modifications in use of resources linked to new treatment
		Availability of CE or CU studies

Adapted from [14]

Risk-sharing agreements for drugs (2)

 Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia

Risk-sharing agreements for drugs

 Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward

Sick individuals and sick populations

Sick individuals and sick populations

 Individus malalts i poblacions malaltes

Una crítica de l’estratègia poblacional de Geoffrey Rose en la medicina preventiva

Rose's Strategy of Preventive Medicine

És part integral de la bona medicina preguntar no tan sols “Quin és el diagnòstic i quin és el tractament?” sinó també “Per què ha succeït això?” i “Es podia haver previngut?”. Aquesta manera de pensar és la que orienta pràcticament tota la recerca clínica i de laboratori sobre les causes i els mecanismes de la malaltia.

Geoffrey Rose 

The economist's view(3)

 Cogs and Monsters. What Economics Is, and What It Should Be

The economist's view (2)

 The New Economics.  A Manifesto

The economist's view

 The Economist’s View of the World And the Quest for Well-Being

Table of Contents

Introduction

Part I. Useful Concepts:

1. Opportunity Cost

2. Marginalism

3. Economic Incentives

Part II. Government and Markets, Efficiency and Equity:

4. Government and the Economy

5. Economists and Equity

6. Externalities and the Government Agenda

Part III. The Limits of Economics:

7. The Economist's Consumer and Individual Well-Being

8. Representatives, Deliberation, and Political Leadership

9. Conclusion.

The five essential healthcare suppliers

 Taking access to the next level: mobilising five essential healthcare sectors

There are five groups that are crucial: Big Pharma, generic medicine manufacturers, vaccine manufacturers, diagnostics companies and medical gas companies. 

In all cases, there are a few dominant players that have a big impact on healthcare

The ethics of direct-to-consumer tests

 The Ethics of Direct-to-Consumer Testing